XELOX化疗方案用于老年晚期胃癌患者治疗的近期临床疗效和不良反应

The Short-term Clinical Efficacy and Adverse Reactions of XELOX Chemotherapy for the Treatment of Elderly Patients with Advanced Gastric Cancer

目的：探讨XELOX化疗方案对老年晚期胃癌的近期临床疗效和用药安全性。方法：将我院2010年2月-2012年2月收治的58例老年晚期胃癌患者随机分为对照组与观察组，分别采取FOLFOX6化疗方案和XELOX全身化疗，比较两组患者近期临床疗效及不良反应发生情况。结果：观察组有效率为68.97%，明显高于对照组的37.93%（P〈0.05）；观察组不良反应发生率为10.34%，明显低于对照组的31.03%（P〈0.05）。结论：XELOX化疗方案对老年晚期胃癌具有较好的近期临床效果，可明显改善患者生活质量，且不良反应少，值得临床推广和应用。

Objective：To investigate the clinical efficacy and drug safety of XELOX chemotherapy for elderly patients with advanced gastric cancer.Methods：58 elderly patients with gastric cancer were treated in our hospital from February 2010 to February 2012 were randomly divided into control group and observation group, and the control group was given FOLFOX6 chemotherapy and the observation group was given XELOX of systemic chemotherapy, the short-term clinical efficacy and adverse reactions occurrence of the two groups were compared.Results：The effective rate of the observation group was 68.97% higher than 37.93%of the control group （P〈0.05）; the incidence of adverse reactions of the observation group was 10.34% lower than 31.03% of the control group （P〈0.05）.Conclusion：XELOX chemotherapy program for elderly patients with advanced gastric cancer have better short-term clinical effects, it can significantly improve the quality of life of patients, and it has fewer adverse reactions, which is worth to be applied in clinical.